Stable gastric pentadecapeptide BPC 157 is a novel anti-ulcer peptide, used in trials for the treatment of ulcerative colitis and now multiple sclerosis. That fifteen amino acid molecule is likely mediator of Robert’s stomach cytoprotection/adaptive cytoprotection and organoprotection, as well as novel mediator of the Selye’s stress coping response, to reestablish the homeostasis. First, BPC 157 exhibits stomach cell protection in order to maintain stomach integrity against various noxious agents (Robert’s killing cell by contact) and continuous presence in gastric mucosa and gastric juice. Additionally, it protects against the adverse effects of alcohol and NSAIDs on the stomach epithelia and other epithelia, i.e., skin, liver, pancreas, heart, (organoprotection), and brain, and thereby suggests its use for the concept of woundhealing. BPC 157 also has an effect on blood vessels, resulting in new vessel recruitment that circumvents the vessel occlusion, presenting additional shunting and rapid bypassing loops to rapidly reestablish blood flow integrity (ischemic/reperfusion colitis; duodenal lesions; cecum perforation; inferior caval vein occlusion). Lastly, BPC 157 counteracted tumor cachexia, muscle wasting, increase of proinflammatory / pro-cachectic cytokines such as IL-6 and TNF-α, significantly corrected deranged muscle proliferation as well as myogenesis through the changes in the expression of FoxO3a, p-AKT, p-mTOR, and P-GSK-3β (mitigating cancer cachexia).